Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FNR5T
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $18,457
Award facts
- Contract value 100% obligated
- $18,456.67 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $18,456.67 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injections on January 13, 2026, with an ultimate completion date of January 14, 2026. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is executed under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2031, which serves as the primary vehicle for delivering comprehensive pharmaceutical products and medical supplies to support military healthcare programs globally.
Dupixent (dupilumab) is a specialty biologic medication used to treat moderate-to-severe eczema, asthma, and chronic rhinosinusitis, and this delivery order reflects the Defense Logistics Agency's need to supply this prescribed medication to military treatment facilities and veterans' healthcare programs. AmerisourceBergen, as a major pharmaceutical distributor and healthcare solutions provider, holds significant federal contracting experience across multiple therapeutic domains and serves as a critical vendor for defense medical procurement. The non-set-aside nature of this award and AmerisourceBergen's established relationship with the DLA demonstrate the company's proven capability to meet federal procurement requirements through open competition.
Quick answers
Who was awarded contract SPE2DR26FNR5T?
SPE2DR26FNR5T was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 13, 2026.
How much is contract SPE2DR26FNR5T worth?
The government has obligated $18,457 on SPE2DR26FNR5T.
Is contract SPE2DR26FNR5T an order under another contract?
Yes. SPE2DR26FNR5T is a delivery order under SPE2DR25D1021, an indefinite delivery contract.
Was contract SPE2DR26FNR5T competed?
The extent of competition for SPE2DR26FNR5T was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award